Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Sweden / NCT06153888
Recruiting Not applicable

ULtrafiltration-Rate Induced CArdiac Strain (ULRICA) - Study

NCT06153888 · tracked via the Priya Life Science Sweden tracker
Sponsor
Umeå University
Phase
Not applicable
Started
2023-03-20
Last updated
2024-12-16

Condition(s) studied

Fluid OverloadDialysis; Complications

Investigational drug(s) / intervention(s)

Ultrafiltration rate

Ultrafiltration rate: Fluid removal during HD will be linear. The time on HD for fluid removal is adjusted after a formula for interdialytic weight gain / removal time (see Goto et al 2023).

Study summary

Patients performing chronic hemodialysis (HD) retain more or less water between dialyses. The water is removed by ultrafiltration and usually during the cleansing of waste products - the HD. The length of HD is usually the same as the time of fluid removal while sometimes this may differ. There is no clear guideline. In previous research the investigator noted that the heart releases more NT-pro-BNP during HD in numerous of the patients.

The present study aims to clarify if the speed of fluid removal during HD is a factor that may alter the release of cardiac markers during HD. If so the recommendations for the prescription of HD can be updated.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult HD patients with an intra-dialytic weight gain (IDWG) ≥2.5% of target weight over the long interval (3 days) prior to inclusion. * Patients need to be able to understand the study information * Patients need to be able to give consent. Exclusion Criteria: * Active systemic inflammatory state such as extensive malignancy or acute septic infection. * Uncontrolled hyperphosphatemia decided by the local routine of the physician (due to somewhat decreased efficacy of the low flux filter to eliminate phosphate)

Primary outcome measure(s)

  • Change in NT-pro-BNP (proBNP) — Per patient: two dialyses within 8 days; Study period:1 year
    The investigation focuses on the marker for cardiac strain pro-BNP (ng/L). Question: Does the heart get less release of markers for cardiac strain upon a slower speed of fluid removal.

Trial sites (1)

FacilityCityRegionStatus
Region Vasterbotten, Norrlands Universitetssjukhus, Dialysen Umeå Sweden Recruiting

More Umeå University trials in Sweden

The eHealth Diabetes Remission Trial Recruiting
Clinical Effectiveness of TARA Compared to Standard Treatment for Adolescents and Young Adults With Depression Active, not recruiting
Prognostic Factors in Periampullary Tumors and Cysts Recruiting
A Comparative Study of Stem and Cup Fixation and Polyethylene Wear Active, not recruiting
Abdominal Rectus Diastasis Microscopy and Rehabilitation (AMIRE) Active, not recruiting

Other trials for the same condition

Timing of Renal Replacement Therapy in the Critically Ill Patients Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06153888 on ClinicalTrials.gov ↗ ← All trials in Sweden